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Abstract  
Background: Nocebo nausea is a debilitating and prevalent side effect that can 
develop after conditioning occurs between cues present in the treatment context and 
the experience of nausea. Interventions that retard conditioning may therefore be able 
to reduce nocebo nausea.  
Purpose: To test whether ‘latent inhibition’, where pre-exposing cues in the absence 
of an outcome retards subsequent learning about those cues, could reduce nocebo 
nausea in healthy adults.  
Methods: We examined this possibility using a Galvanic Vestibular Stimulation 
(GVS) model of nausea in healthy participants, with pre-exposure to the treatment 
cues achieved using a placebo version of GVS.  
Results: In Experiment 1 we found clear evidence of conditioned nocebo nausea that 
was eradicated by latent inhibition following pre-exposure to placebo stimulation. 
Experiment 2 tested whether deception, which may be unethical in clinical settings, 
was necessary to produce latent inhibition by including an open pre-exposure group 
informed they were pre-exposed to placebo stimulation. Experiment 2 replicated the 
latent inhibition effect on nocebo nausea following deceptive pre-exposure from 
Experiment 1 and found that open pre-exposure was just as effective for reducing 
nocebo nausea. In both experiments, there was an interesting discrepancy found in 
expectancy ratings whereby expectations appeared to drive the development of 
conditioned nocebo nausea, but were not responsible for its retardation through latent 
inhibition.  
Conclusions: These findings have significant clinical implications. Applying open 
pre-exposure in clinical settings may effectively and ethically reduce the development 
of nocebo effects for nausea and other conditions via latent inhibition.  
Manuscript ( WITHOUT authors
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 Latent inhibition reduces nocebo nausea, even without deception 
Nausea is a pervasive problem in both clinical (e.g. chemotherapy, 
anaesthesia) and non-clinical settings (e.g. aviation, maritime). In its extreme, it 
impairs quality of life (1-3) and can lead to malnutrition and food aversions (4). Even 
in its moderate form, it is inherently unpleasant and can interfere with daily 
functioning. Importantly, evidence indicates that non-pharmacological factors can 
significantly contribute to nausea via the nocebo effect (see 5, 6 for reviews). Yet, 
there have been surprisingly few attempts to date to develop interventions to reduce 
nocebo nausea.  
The nocebo effect is when treatment cues, in and of themselves, lead to 
adverse outcomes, and has been used to explain why so-called ‘non-specific’ side 
effects occur in many patients, i.e. adverse effects which are not a direct result of the 
pharmacological action of a drug (7). Classical conditioning is a key source of the 
nocebo effect (8). In the case of nocebo nausea, cues signaling treatment, for example 
the sensations of injection or ingesting a pill, can become associated with a nauseating 
agent such that these cues themselves become capable of eliciting nausea. A number 
of laboratory studies clearly demonstrate the contribution of conditioning to nocebo 
nausea. For example, it has been found that if an oral stimulus (a Listerine strip) is 
paired with rotation-induced nausea then this oral stimulus subsequently enhances 
nausea (9), and that re-exposure to placebo galvanic stimulation after nauseating 
galvanic stimulation leads to nocebo nausea (10). Furthermore, the contribution of 
conditioning to nocebo nausea is not confined to the laboratory.  Patients receiving 
chemotherapy can experience increased nausea as a function of the number of 
treatment cycles, and treatment cues previously paired with nausea can give rise to 
nausea even before the chemotherapeutic agent has been delivered (see 11 for a 
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review).  
Given the role of conditioning in the development of nocebo nausea, any 
intervention that impairs conditioning should inhibit nocebo nausea. Latent inhibition 
is one such procedure. It is the learning phenomenon whereby pre-exposure to a cue 
in the absence of any outcome impairs future learning about that cue. For example 
presenting a light alone before pairing it with a shock increases the time it takes an 
animal to learn the light-shock pairing (12). Latent inhibition is a well-documented 
and robust effect in non-human animals, having been observed for a wide range of 
cues and outcomes (for a review, see 13). Interestingly, this includes animal nausea 
conditioning studies in which cue pre-exposure to a to-be-conditioned cue has been 
found to reduce conditioned taste (e.g. 14) and place aversions (15). While the exact 
mechanisms of latent inhibition continue to be debated, it has been suggested that the 
initial unreinforced pre-exposure of a cue reduces its novelty or salience. This is 
proposed to lead the organism to direct less attention towards it when it is later 
encountered, hence reducing the extent of conditioning when it is subsequently 
reinforced (16).  
To date, only two studies have examined whether latent inhibition can reduce 
conditioned nausea in humans, both of which involved pre-exposing healthy 
participants to a rotation chair prior to their experience of nauseating rotation. These 
studies tested the hypothesis that the pre-exposure to the chair would inhibit the 
participants learning to associate the chair with nausea when they were later rotated in 
it. The first study found evidence that pre-exposing healthy participants to a the 
rotation context may have reduced anticipatory nausea, i.e. nausea when the 
participants were placed in the rotation context but not rotated (17). Conversely, the 
second also using rotation found evidence that pre-exposure may have actually 
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facilitated the development of anticipatory nausea (18).  
However, these two abovementioned studies have some potentially important 
limitations. First, both lacked “no conditioning” controls. In the absence of direct 
evidence that this paradigm would ordinarily lead to conditioned nausea compared 
with no conditioning, it is difficult to determine whether the addition of pre-exposure 
retarded conditioning via latent inhibition. Second, the studies focused on pre-
exposing environmental cues to reduce nocebo nausea in the anticipatory period. 
Indeed, neither study found that pre-exposure reduced nausea in response to actual 
rotation (i.e. ‘reactive’ nausea).  This limited focus is consistent with the historical 
emphasis in this area on anticipatory nausea (e.g. 11, 19, 20), which may be because 
anticipatory nausea is easier to isolate from toxicity-induced nausea than its reactive 
counterpart as it occurs before treatment has been administered. However, there are at 
least three reasons that nocebo factors may be more important in reactive nausea: a) 
the reactive period involves all cues that could be conditioned, whereas the 
anticipatory period necessarily involves fewer cues because it occurs before 
treatment, b) the cues specific to the reactive period may be more salient, as they are 
often more distinctive and tactile (e.g. infusion apparatus) than environmental cues 
present during both anticipatory and reactive periods, and c) the reactive cues are also 
more likely to be cognitively associated with nausea, since patients will know that 
they are the vehicle for the nauseating agent. All of these factors are known to 
facilitate conditioning, and may diminish or even prevent learning about less salient 
(e.g. environmental) cues (21). Third and related, the use of rotation chairs is limiting 
because there is no “placebo” setting in which the nocebo cues can be presented in the 
absence of the unconditioned stimulus that produces nausea. This means that every 
time a participant is rotated, their reactive response is a combination of the 
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unconditioned and conditioned nauseous response, which prevents a pure test of 
nocebo nausea.   
The current study therefore tested whether pre-exposure could reduce nocebo 
nausea via latent inhibition using a new model of nocebo nausea based on Galvanic 
Vestibular Stimulation (GVS) that we recently developed (10).  Through mild 
stimulation of the vestibular system, GVS causes a mismatch between visual and 
vestibular cues that produces nausea in most healthy adults. GVS is ideal because it 
has both ‘active’ and ‘placebo’ settings. This allows pre-exposure of cues normally 
specific to the reactive period and provides a critical test of the pure conditioned 
nocebo nausea in the reactive period, without the nauseating agent, but with all 
treatment cues present. Given that the applicability of any such intervention to applied 
settings rests on its ethicality, Experiment 2 also tested whether the latent inhibition 
effect required deception, which to our knowledge has never previously been tested.  
In another novel extension of previous studies of nocebo nausea, participants’ 
expectancies were also assessed throughout to determine the extent that they predicted 
nocebo nausea and whether it was sensitive to latent inhibition. 
Experiment 1 
Experiment 1 first aimed to establish whether latent inhibition could reduce 
anticipatory and/or reactive nocebo nausea, with the appropriate control. Specifically, 
it tested whether participants who were pre-exposed to placebo GVS (group PreX) 
would experience less nocebo nausea than those who did not (group NoPreX) and, 
critically, compared this with a control group who never experienced active GVS to 
verify that conditioning had occurred. 
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Method 
Participants 
Participants were 45 undergraduates from the University of Sydney, who were 
awarded partial course credit for their participation or reimbursed at a rate of 
AUD$15/ hour for their time. Participants had to be aged 18 or over and not suffering 
from a known medical condition to participate. They had an average age of 21.1 years 
(SD= 4.1) and 24 were female, with 8 females allocated to each group after 
stratification of randomization separately for each gender. The project received 
approval from the University of Sydney Human Research Ethics Committee. 
Design  
The experimental design is displayed in Table 1. The control group received 
no experience with active stimulation, whereas the two experimental groups 
experienced equivalent active stimulation during acquisition. Within the two 
experimental groups, the PreX group received pre-exposure prior to placebo GVS 
during training, whereas the NoPreX group did not. During the test phase on Day 3, 
all groups received placebo stimulation, and therefore any differences would be as a 
result of either pre-exposure or conditioning. Nausea was assessed using numerical 
ratings before and after stimulation.  
[Table 1 about here] 
Apparatus 
Nausea was induced using Galvanic Vestibular Stimulation; see Quinn, 
MacDougall and Colagiuri (10) for a more detailed description of the apparatus. In 
both types of stimulation, the wave sent was a pseudorandom sum of sines signal with 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Po
st-
pri
nt
 8 
peak amplitude ±4mA. The type of stimulation was set by varying whether both sides 
of the vestibular system received the same stimulation, termed monopolar or 
‘placebo’ stimulation, or whether one wave was sent to one side, and the additive 
inverse to the other, known as bipolar or ‘active’ stimulation. In the former there 
tends to be little perception of movement, whereas there is a large motion mismatch in 
the latter that has been shown to lead to nausea (10, 22). During both types of 
stimulation the individual will experience a mild prickling or itching sensation at the 
electrode site, and often the perception of a metallic taste due to the incidental 
stimulation of taste buds (23), making them difficult to distinguish. The stimulator 
was attached to participants using three 10cm² electrode pads (one behind each ear 
over the mastoid bone, and one centered on the v5 vertebra) and copper wires.  
Procedure  
Participants were instructed before attending the experiment to eat a small 
meal approximately two hours before their session, and were assessed individually at 
the same time of day across three days, with no more than two days between sessions. 
On the first day ‘pre-exposure’, participants were given the cover story that the 
experiment was exploring the effect of vestibular stimulation on spatial awareness to 
reduce demand characteristics. Described in more detail previously (10), participants 
were told that the researchers were using galvanic stimulation to understand how 
experiencing motion mismatch may affect their ability to make sophisticated spatial 
discriminations, and that unfortunately motion sickness sometimes resulted from this 
stimulation. Participants then filled out a demographics questionnaire and were told 
that for their safety during the experiment they would also be asked to fill out a 
‘symptom questionnaire’ which asked them to rate six nausea-related symptoms (urge 
to vomit, stomach awareness, nausea, headache, fatigue and dizziness) and two 
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unrelated symptoms on a numeric rating scale from 0= not at all to 10= severe. An 
expectancy question was embedded within the questionnaire, which asked 
participants how much they expected to experience motion sickness during the day’s 
session (0= not at all to 10 = very much so), as well as a bogus expectancy question 
about their cognitive performance. The control and NoPreX groups were then 
informed that the day’s session would be a baseline assessment of their spatial 
awareness, with no GVS, and completed a 25 minute computerized visual search task 
where they had to repeatedly find a ‘T’ hidden in among ‘L’ distractors. The PreX 
group were instead attached to the GVS and received 25 minutes of placebo 
stimulation while undertaking the same spatial task. All three groups then filled out a 
second symptom questionnaire. 
On the second ‘acquisition’ day, the baseline symptom questionnaire was 
repeated, after which GVS was administered to all participants. The control group had 
placebo stimulation, whereas the two conditioning groups (NoPreX and PreX) had 
active stimulation. All participants did a series of bogus spatial tasks (ball toss, 
balance, dot-to-dot, pattern completion) as per Quinn et al. (10) until they had 
received 25 minutes of stimulation. These tasks were administered both to uphold the 
cover story, as well as enhance the perception of motion mismatch by inducing 
movement. After this, participants completed the post symptom questionnaire. 
On the last day, ‘test’, all participants had the same baseline questionnaire, 
received placebo stimulation while undertaking the same 25 minute computerized 
task as on Day 1, and then had the same post questionnaire. The computerized task 
was used on Day 1 and 3 as being seated minimizes participants’ ability to discern the 
difference between placebo and active stimulation. They then underwent a 
manipulation check which was an open response question asking them what they 
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thought the aims of the experiment were. They were then thanked and fully debriefed.  
Analysis 
 A participant’s nausea rating score was calculated by summing the rating of 
each of the six nausea-relevant symptoms.    
Anticipatory nausea  
First, an assessment of anticipatory nausea was performed by comparing the 
baseline nausea ratings between the three groups. To determine whether there were 
any changes across the experiment as a result of the conditioning manipulations, a 
mixed 3 x (2) ANOVA was undertaken comparing the three groups on their Day 1 
and Day 3 baseline nausea ratings.  
Reactive nausea  
Provided no baseline differences were found, a participant’s nauseous 
response score was calculated as the difference between their post and baseline 
nausea ratings, with a possible range from -60 to 60, and analysed in a between 
subjects ANOVA separately for each day.  
Expectancies  
Baseline (Day 1) expectancies were assessed using a between-subjects 
ANOVA to ensure randomization had been successful and that no baseline 
differences were present. Expectancies were then compared across groups using a 
between-subjects ANOVA separately for Day 2 and Day 3. 
Manipulation check  
Responses to the manipulation check “Please describe the aims of the 
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experiment in your own words” were coded for 0= "no mention of nausea/ motion 
sickness", 1= "mention of nausea/motion sickness but in its effect on spatial 
awareness (ie. as an independent variable rather than dependent variable), and 2= 
"mention of nausea/ motion sickness as some form of dependent variable". A 
Pearson’s chi-square analysis was then undertaken comparing the frequencies of these 
answers across groups. 
In all ANOVA for between group differences (other than those computed only 
to compare baseline levels), planned pairwise comparisons (where each possible pair 
of means is compared) were undertaken using the Tukey’s Honest Significant 
Difference (HSD) procedure. Analysis was conducted using SPSS (V20) and results 
were considered statistically significant when p < .05. 
Results 
Raw baseline and post-stimulation symptom mean ratings for the three groups 
across the three days are reported in Table 2. Prior to analysis, three participants were 
excluded due to equipment failure, one withdrew consent before study completion, 
and one did not complete the study and was not contactable. Recruitment was 
continued until n=15 in each group, resulting in a final N=45 included in analyses.   
[Table 2 about here] 
Anticipatory nausea  
There were no differences in baseline nausea ratings between groups on any of 
the days, indicating, as expected, no evidence of failure of randomization or 
anticipatory nausea (smallest p= .699). Averaged across the three groups, there was 
no significant difference between baseline scores on Day 1 and Day 3, η𝑝
2 =.053, 
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F(1,42)= 2.35, p=.133, with the means actually suggesting a reduction in baseline 
nauseas by Day 3, no main effect of group averaged across the two times, η𝑝
2 = .005, 
F(2,42)= 0.09, p=.909, and no interaction between them, η𝑝
2 =.034, F(2,42)= 0.73, 
p=.486. 
Reactive nausea  
As there were no differences in baseline ratings on any day, nauseous response 
scores were calculated for each day separately and are depicted in Figure 1. On the 
pre-exposure day (Day 1), Tukey’s HSD revealed no significant differences in 
nauseous response scores between any group (smallest p=.327). During acquisition on 
Day 2, the NoPreX group had significantly higher nauseous response scores than the 
control group, η𝑝
2 =.417, F(1,42)=29.99, p<.001, and the PreX group, η𝑝
2 =.136, 
F(1,42)=6.59, p=.036, and that the PreX group also had significantly higher nauseous 
response scores than the control group, η𝑝
2 =.168, F(1,42)=8.46, p=.016. On test (Day 
3), the NoPreX group again had significantly higher nauseous response scores than 
the control group, η𝑝
2 =.127, F(1,42)=6.09, p=.046, indicating conditioned nocebo 
nausea. Further, the PreX group had significantly lower nauseous response scores 
than the NoPreX group, η𝑝
2 =.138, F(1,42)=6.74, p=.034, and did not differ 
significantly from controls, η𝑝
2 <.001, F(1,42)=.02, p=.991, indicating a significant 
latent inhibition effect. 
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Figure 1. Mean nauseous response scores with 95%CI for the three groups during 
pre-exposure (Day 1), acquisition (Day 2) and test (Day 3). 
Expectancies 
Expectancy ratings are depicted in Figure 2. On Day 1 Tukey’s HSD did not 
reveal any differences between groups at baseline (smallest p=.592), or on Day 2 
before acquisition (smallest p=.717). On test (Day 3) the NoPreX group reported 
significantly higher expectancies than the control group, η𝑝
2 =.282, F(1,42)=13.72, 
p=.002, the PreX group reported numerically but non-significantly higher 
expectancies than the control group, F(1,42)=4.38, η𝑝
2 =.111, p=.103, and the NoPreX 
and PreX groups did not differ significantly, F(1,42)=2.59, η𝑝
2 =.069, p=.254.  
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Figure 2. Mean with 95%CI expectancy ratings for the three groups prior to pre-
exposure on Day 1, prior to acquisition on Day 2 and before test on Day 3.  
A post hoc, exploratory regression was also undertaken to determine the 
extent to which expectancies actually predicted the nauseous response, and it was 
found that controlling for baseline expectancies, expectancy on Day 3 predicted a 
significant amount of the variance in Day 3 nauseous response score, with a one unit 
increase in expectancy leading to a 1.4unit higher nauseous response score, 
t(42)=2.94, p=.005.  
Manipulation check 
Of the 45 participants tested, none correctly identified nausea as the dependent 
variable. There were 11 participants who did mention nausea but who thought it 
might be an independent variable along with the experience of motion rather than 
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realising it was a dependent variable; 2 controls, 4 in the NoPreX group and 5 in the 
PreX group. The likelihood of mentioning nausea as an independent variable did not 
differ significantly between the groups, 𝜒2 = 1.68, p=.430. 
Discussion 
Experiment 1 found clear evidence of conditioned reactive nocebo nausea and 
its latent inhibition through pre-exposure. On the test day on Day 3, although all 
groups received the placebo stimulation, the NoPreX group reported more nausea 
than controls, suggesting that conditioning had developed, and most interestingly, also 
reported more nausea than the PreX group, suggesting that pre-exposure had 
attenuated this effect. In fact, the latent inhibition effect was so strong that there was 
no evidence any nocebo nausea developed in the PreX group at all. It was also 
interesting to observe that the latent inhibition effect was present by the end of 
acquisition on Day 2. This suggests that participants were already learning about the 
stimuli during this acquisition session (see General Discussion for further discussion 
of this possibility). 
On test (Day 3) those without pre-exposure reported stronger expectancies for 
nausea than controls, but the difference between the PreX and NoPreX groups did not 
reach significance. This suggests that reported expectancies were affected by 
conditioning, but not by latent inhibition. This may be because the expectancy 
question was carefully embedded within a larger questionnaire and asked about 
“motion sickness” rather than nausea. This was done purposefully to avoid alerting 
participants to nausea as a dependent variable, but it may also have reduced the 
conclusions that can be drawn from this question in terms of the importance of 
expectancies. However, taken at face value the expectancy data suggest that explicit 
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reasoning about the likelihood of nausea occurring may facilitate the development of 
conditioned nausea, but may not be as strongly involved in the retardation of this 
conditioning.  
Experiment 1, therefore, suggests that pre-exposure to reactive cues may be 
able to prevent nocebo nausea from developing in clinical settings, e.g. in 
chemotherapy. However, this procedure concealed the real purpose of pre-exposure; 
an equivalent clinical application would presumably involve deceiving patients into 
thinking that they were actually receiving their first treatment during pre-exposure, 
whilst really delivering an inert agent. As a clinical treatment, this would raise serious 
ethical concerns. Thus it is also important to determine whether the latent inhibition 
effect persists when patients know the pre-exposure is pharmacologically inactive.  
Experiment 2 
Experiment 2, therefore, tested whether deception was required to produce 
latent inhibition. In Experiment 1, participants were not told that the device had two 
different settings, and those in the PreX group would most likely have assumed that 
the stimulation they received on the first day was representative of what they would 
receive on all three days. In Experiment 2, we included a new ‘open’ pre-exposure 
group who were informed about the two different settings of the device and explicitly 
told that they were receiving placebo stimulation during pre-exposure on Day 1. Such 
a procedure avoids any of the ethical concerns associated with standard pre-exposure.   
Method 
Participants  
Participants were 45 undergraduates from the University of Sydney, none of 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
P
st-
pri
nt
 17 
whom had participated in the first experiment, who were awarded partial course credit 
for their participation or reimbursed at a rate of AUD$15/ hour for their time. 
Participants had to be aged 18 or over and healthy to participate. They had an average 
age of 19.82 (SD= 3.4) and 24 were female, with 8 females allocated to each group 
after stratification of randomization separately for each gender. The project received 
approval from the University of Sydney Human Research Ethics Committee. 
Design 
The experimental design is displayed in Table 3. The control group was 
omitted as both Experiment 1 and a previous experiment in our laboratory (Quinn et 
al. 2015) demonstrated that placebo GVS does not unconditionally induce nausea, and 
therefore that any evidence of nausea in the conditioning groups reflects conditioning-
induced nocebo nausea. The design included the same NoPreX and PreX groups as 
Experiment 1, with the addition of the Open PreX group. The Open PreX group were 
informed that the device has both monopolar and bipolar settings, and that 
participants would be receiving monopolar on Day 1 and then bipolar on the second 
two days. They were told that while bipolar stimulation can lead to nausea, monopolar 
usually does not, and that starting with monopolar stimulation usually reduces the 
individual’s response to the bipolar stimulation they would get on the last two days 
(they were not provided with an explanation for how this might occur). The design 
still required deception with respect to Day 3 stimulation to allow an assessment of 
purely conditioned nausea, and so all participants on the test day were told that they 
were receiving bipolar stimulation, when in fact they were all receiving the placebo. 
But this simply served as the test of the nocebo effect.  
[Table 3 about here] 
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Procedure  
The procedure of Experiment 2 was identical to that of Experiment 1, except 
for the different instructions about the GVS settings, which was delivered 
immediately after the first baseline questionnaire.  
Analysis  
The analysis was the same as for Experiment 1, except that rather than 
pairwise comparisons, planned mutually orthogonal contrasts were conducted as these 
better reflected the design of Experiment 2, i.e. two latent inhibition groups versus a 
no-prexposure group. This first contrast compared the NoPreX group to the two pre-
exposure groups (PreX and Open PreX), and the second compared the two pre-
exposure groups themselves.  
Results 
Raw baseline and post nausea mean ratings for the three groups across the 
three days are reported in Table 4. Prior to analysis, two participants were excluded 
for insufficient English, one due to equipment failure, two withdrew consent before 
study completion, and one did not complete the study and was not contactable. 
Recruitment was continued until n=15 in each group, resulting in a final N=45 
included in analyses.   
[Table 4 about here] 
Anticipatory nausea 
As with Experiment 1, there were no differences in baseline nausea ratings 
between groups on any of the days, indicating, as expected, no evidence of failure of 
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randomization or anticipatory nausea (smallest p= .295). Averaged across the three 
groups baseline nausea ratings were lower on Day 3 than Day 1, η𝑝
2 =.244, F(1,42)= 
13.57, p=.001.  There was no main effect of group averaged across the two times, η𝑝
2 
=.023, F(2,42)= 0.49,p=.619, and no interaction between them, η𝑝
2 =.043, F(2,42)= 
0.935, p=.401.  
Reactive nausea 
As there were no differences in baseline ratings on any day, nauseous response 
scores were calculated for each day separately and are depicted in Figure 3. On Day 1 
during pre-exposure, contrast analysis revealed no difference between the NoPreX 
and pre-exposure groups, η𝑝
2 =.044, F(1,42)=1.92,p=.173, but that the PreX group 
reported higher nauseous response scores than the Open PreX group, η𝑝
2 =.121, 
F(1,42)=5.76, p=.021. On Day 2, during acquisition the nauseous response scores 
were numerically lower in the two pre-exposure groups compared with the NoPreX 
group as in Experiment 1, but this did not quite reach statistical significance, η𝑝
2 
=.078, F(1,42)=3.56, p=.066, and there was no difference between the two pre-
exposure groups themselves, η𝑝
2 =.006, F(1,42)=0.24, p=.63. On Day 3 contrast 
analysis revealed that the two pre-exposure groups reported lower nauseous response 
scores than the NoPreX group F(1,42)=5.86, η𝑝
2 =.122, p=.020, indicating a 
significant latent inhibition effect. Further, there was no difference between the two 
pre-exposure groups, η𝑝
2 =.003, F(1,42)=0.11, p=.677, indicating that they were 
equally effective at inducing latent inhibition. 
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Figure 3. Mean nauseous response with 95%CI for the three groups during pre-
exposure (Day 1), acquisition (Day 2) and test (Day 3). 
Expectancies  
Expectancy ratings are depicted in Figure 4. On Day 1 at baseline, there were 
no between-subject differences in reported expectancies η𝑝
2 =.018, F(2,42)= 0.38, p 
=.687. On Day 2, controlling for baseline expectancies, contrasts found that there was 
no difference between the NoPreX and two pre-exposure groups on average, η𝑝
2 
=.032, F(1,42)= 1.38, p=.248, but that the Open PreX group reported numerically 
higher expectancies than the PreX that did not reach statistical significance, η𝑝
2 =.080, 
F(1,42)=3.64, p=.064. On Day 3, controlling for baseline expectancies there was no 
difference between the NoPreX and pre-exposure groups, η𝑝
2 = .004, F(1,42)= 0.15, 
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p=.70, and no difference between the two pre-exposure groups themselves, η𝑝
2 =.014, 
F(1,42)= 0.58, p=.451. A post hoc regression on the relationship between 
expectancies and nausea at test controlling for  baseline expectancy, found that 
expectancies on Day 3 did not predict a significant amount of the variance in Day 3 
nauseous response scores, t(42)=1.15, p=.258.  
 
Figure 4. Mean with 95%CI expectancy ratings for the three groups prior to pre-
exposure on Day 1, prior to acquisition on Day 2 and before test on Day 3.  
Manipulation check 
Following the criteria set out in the analysis section of Experiment 1, of the 45 
participants, one participant (from the PreX group) was classified as reporting that 
nausea was a dependent variable. There were nine participants who mentioned nausea 
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but who referred to it as an independent variable that might affect spatial awareness 
rather than reporting it was a dependent variable; two in the NoPreX group, two in the 
PreX group and give in the Open PreX group. The rates of mentioning nausea as an 
independent variable, dependent variable or not mentioning it at all in their 
description of the aims did not differ significantly between the groups, 𝜒2 =
4.400, p>.250. 
Discussion 
Experiment 2 replicated the latent inhibition effect of Experiment 1, finding 
that on average the two pre-exposure groups reported less nausea than the NoPreX 
group on test (Day 3). Most interestingly, informing participants that the stimulus 
they were pre-exposed to was not active did not reduce the efficacy of latent 
inhibition. This finding has significant clinical implications, as it suggests that an 
application of an open pre-exposure intervention in clinical settings may be able to 
produce a latent inhibition effect and reduce the development of nocebo nausea.  
The pattern of expectancies on test in Experiment 2 again did not show latent 
inhibition, and in training on Day 2 the expectancies appeared to be in the opposite 
direction to the nausea ratings, with the Open PreX group reporting higher 
expectancies for nausea. Experiment 2 did not include a no-conditioning control, but 
these data are broadly consistent with the expectancy data from the conditioning 
groups in Experiment 1. 
General Discussion 
The two experiments presented here provide new evidence that nocebo nausea 
can be reduced through cue pre-exposure and critically, that deception is not required 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Po
st-
pri
nt
 23 
to produce this effect. That is, latent inhibition of nocebo nausea was still observed 
even when individuals knew the pre-exposure was to inactive stimulation.  The study, 
therefore, demonstrates that latent inhibition may be an effective technique to reduce 
nausea in both clinical and other applied settings.  
In terms of applying latent inhibition procedures, it appears that reactive 
nausea will benefit the most. Neither experiment here showed any evidence of 
anticipatory nausea developing. In fact in Experiment 2 there was a significant 
decrease in nausea reporting in the anticipatory period on test relative to the 
beginning of the experiment. This is consistent with our previous research using this 
paradigm (10) as well as the prediction that anticipatory cues are less likely to be 
conditioned than reactive cues. This means that any attempt to use latent inhibition to 
reduce nocebo nausea should focus on reactive cues. In particular, pre-exposing 
patients to the sensations and stimuli that are usually only present while the treatment 
is actually being administered will be key. Critically, the fact that open pre-exposure 
is just as effective as standard pre-exposure ensures that such interventions can be 
used ethically, without impinging on patient autonomy.  
The use of “open-label” placebos, where no deception is provided regarding 
the placebo administered is an emerging area of research. Reviewed in more detail 
elsewhere (8), some studies have observed placebo improvement following open-
label placebo treatment, such as in reducing gastrointestinal distress (24). The current 
study extends this evidence by showing that an open-intervention can also inhibit 
development of a nocebo effect. It is worth noting that in other open-label placebo 
studies, the placebo treatment was accompanied by information about how placebo 
effects can reduce responding. This is similar to the information provided to 
participants in our open group regarding the potential of pre-exposure to reduce 
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nausea. As such, positive instructions during pre-exposure may be a necessary 
component of the intervention to produce symptom improvement. In the current 
study, it is conceivable that the symptom improvement in the open group was 
facilitated by a placebo effect. This explanation also predicts that the open pre-
exposure group should have reported less nausea and lower expectancy for nausea 
than in the hidden pre-exposure group on Day 2, and so does not fully account for the 
observed results. Nevertheless, it may be the case that in the absence of deception, 
latent inhibition requires enhancement from positive instructions. Although this does 
not reduce the clinical applicability of our intervention, determining whether this 
feature of the instructions is necessary for the effect to occur is important to aid 
understanding of the reasoning processes that lead to latent inhibition. 
In a novel extension, this study also assessed patient expectancies. 
Expectancies are often not directly assessed in studies of placebo and nocebo effects, 
but rather are just inferred from the information that participants had been provided 
with. The expectancy data revealed an interesting finding consistent across both 
experiments, where it appeared that explicit expectancies drove the development of 
conditioning, but not its retardation through latent inhibition. Although both of our 
expectancy assessments are vulnerable to methodological criticisms previously 
described, these data do question an account of placebo or nocebo effects that sees 
expectancies as entirely responsible for responding (see 25 for an example). It may be 
that there is a non-conscious or non-expectancy based component of the latent 
inhibition effect that drives the group differences observed, such as reduced attention 
towards the reactive cues or lower levels of anxiety due to their pre-exposure. This 
may also explain why the Open PreX group still experienced latent inhibition even 
when they knew that their experience during pre-exposure would not be predictive of 
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their likelihood for nausea during the experiment. Of course, one would need more 
sensitive indicators of learning outside awareness to claim definitively that non-
conscious learning or placebo responding in the absence of expectancy occurred (26). 
Further, the correlation between expectancies and nauseous response on test in 
Experiment 1 would suggest that they play a role. However, this evidence does 
suggest that if they do play a role, they are likely not the only factor doing so.  
The current study also has important implications for the theories of latent 
inhibition. There has been debate about whether it is possible to observe what has 
been labelled “unmasked” latent inhibition. Le Pelley and Schmidt-Hansen (27) argue 
that many of the human studies that have purported to observe latent inhibition are 
actually observing learned irrelevance, as the stimulus is not being merely pre-
exposed, but is pre-exposed while the attention of participants is deliberately diverted. 
It has been argued that this deliberate ‘masking’ of the cue may be required to 
produce latent inhibition in humans (28), but this would make the effect inconsistent 
with those observed in the animal literature, where animals are free to attend to the 
pre-exposed stimulus, and has important implications for the mechanisms 
underpinning latent inhibition and associative learning more generally. The current 
experiments provide two examples of unmasked latent inhibition in humans, as 
participants were free to attend to the reactive cues during pre-exposure. This, along 
with another recent example of unmasked latent inhibition(29), suggests that in 
contrast to that which Lubow and Kaplan (28) argued, under certain conditions it is 
possible to observe unmasked latent inhibition in human learning. 
There are some limitations to the current experiments worth noting. First, the 
GVS device was novel to participants, with participants unlikely to have even heard 
of it prior to the experiment. Although in our studies individuals were informed that 
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GVS could lead to nausea, given its novelty they may have held weaker beliefs that it 
may cause nausea than would be expected in a clinical setting with a well-known 
treatment (e.g. chemotherapy). One could speculate that latent inhibition would be 
less effective at reducing nocebo nausea in patients with more strongly held beliefs. 
On the other hand, it is also possible that pre-exposure may be even more effective in 
highly expectant patients as there would be larger violation of expectation. This 
would certainly be interesting to explore in future studies. Second, it is possible that 
the Open pre-exposure group realised on test (Day 3) that they were actually receiving 
monopolar stimulation, which then artificially produced a latent inhibition-like effect. 
However we screened for this during the manipulation check, and the trend towards a 
latent inhibition effect during acquisition in this group suggests that conditioning may 
already have been reduced before this. It is also important to note that the researcher 
was not blinded to participants’ group allocation in the current study, and while the 
procedure was systematised to minimise any potential impact of this knowledge, it 
cannot be ruled out entirely. Further research is required to define the parameters of 
the latent inhibition effect, such as how the number and duration of pre-exposures 
should be configured to accommodate longer ‘conditioning’ or treatment sessions 
than the single session used in the present study.   
In summary, the current study provides new evidence that pre-exposing 
reactive cues prior to pairing them with nausea reduces nocebo nausea, and critically 
that this can occur even when presented as an open intervention. Pre-exposing 
reactive cues may, therefore, be a novel and exciting new method of reducing 
maladaptive conditioning in the clinic and would be ethical in the sense that it does 
not require deception.  
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Table 1.  
Design of Experiment 2 showing type of stimulation for each group across the 
experiment. 
 
Group 
Pre-exposure 
Day 1 
Acquisition 
Day 2 
Test 
Day 3 
Control - Placebo  Placebo  
NoPreX - Active  Placebo  
PreX Placebo  Active  Placebo  
 
Table 2.  
The mean (SD) nausea symptom ratings of the three groups across the three days of 
the experiment. 
 Day 1 Day 2 Day 3 
Group Baseline Post Baseline Post Baseline Post 
Controls  
(n = 15)  
5.20 (4.09) 5.33 (5.90) 4.07 (5.09) 6.4 (5.78) 4.73 (5.98) 7.80 (7.12) 
NoPreX 
(n = 15) 
5.80 (6.73) 5.07 (5.55) 4.47 (4.70) 20.87 (11.57) 5.27 (4.80) 14.74 (13.48) 
PreX 
(n = 15) 
6.8 (4.39) 8.87 (5.66) 5.6 (5.74) 15.33 (7.20) 4.40 (3.33) 7.13 (4.84) 
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Table 3.  
Design of Experiment 2 showing type of stimulation for each group across the 
experiment.   
 Pre-exposure 
Day 1 
Acquisition 
Day 2 
Test 
Day 3 
NoPrex - Active  Placebo  
Prex  Placebo  Active  Placebo  
Open PreX  Placebo  Active  Placebo  
 
Table 4.  
The mean (SD) nausea symptom ratings of the three groups across the three days of 
the experiment. 
 Day 1 Day 2 Day 3 
Group Baseline Post Baseline Post Baseline Post 
NoPreX  
(n = 15)  
6.90 (8.02) 5.67 (6.52) 5.07 (5.32) 19.53 (11.64) 3.93 (4.56) 8.33 (8.40) 
PreX 
(n = 15) 
4.53 (3.56) 6.60 (6.22) 3.07 (2.94) 11.60 (8.79) 3.33 (4.50) 5.00 (4.57) 
Open PreX 
(n = 15) 
5.67 (4.97) 4.53 (4.15) 3.20 (2.78) 13.00 (9.78) 2.33 (2.97) 3.53 (3.81) 
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